Avastin - bevacicumab toegevoegd aan Temodal en irinitocan geeft nagnoeg zelfde resultaten en zelfde toxiciteitspatroon van nieuw gediagnosteerde hersentumoren, glioblastoom multiforme dan zonder avastin

27 augustus 2018: Zie ook dit artikel:

https://kanker-actueel.nl/avastin-bevacizumab-toegevoegd-aan-chemo-temozolomide-temodal-faalt-en-geeft-zelfs-slechtere-overall-overleving-op-1-jaar-bij-een-behandeling-van-een-hersentumor-glioblastoma.html

16 mei 2011: Bron: Clin Cancer Res. 2011 Apr 29. [Epub ahead of print]

Een nieuwe fase II studie heeft uitgewezen dat wanneer Avastin - bevacicumab post operatief en na bestraling aanvullend op temodal - temolozomide en irinitocan wordt gegeven bij nieuw gediagnosteerde hersentumoren (glioblastoom), het min of meer zelfde toxiciteitspatroon optreedt en ook de resultaten nagenoeg hetzelfde zijn op overlevingstijd en ziektevrije tijd. Vergeleken met wat statistisch mocht worden verwacht zonder Avastin. Maar dus ook deze fase II studie bij 72 patienten is niet gerandomiseerd uitgevoerd. Lees hier veel meer over Avastin - bevacicumab, en de grote twijfels die er zijn over de therapeutische effecten en bijwerkingen bij dit medicijn, ook bij andere vormen van kanker dan hersentumoren

Hier het abstract van de studie gepubliceerd in Clinical Cancer Research, waar u tegen betaling het volledige studierapport op kunt vragen.

The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide and Irinotecan for Newly Diagnosed Glioblastoma.

+ Author Affiliations

¹The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center
²Neurosurgery, Duke University Medical Center
³Biostatistics, Duke University Medical Center
⁴Radiation Oncology, Duke University Medical Center
⁵Division of Neurosurgery, Duke University Medical Center
⁶Surgery, Duke University Medical Center
⁷Department of Surgery, Duke University Medical Center
⁸Department of Pathology, Duke University Medical Center

*↵ Corresponding Author:
James J Vredenburgh, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, 047 Baker House, Brown Zone, Duke Hospital South, Durham, NC, 27710, United States vrede001@mc.duke.edu

Abstract

Purpose: To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide and irinotecan for newly diagnosed glioblastoma patients is safe and effective.

Experimental Design: Seventy five patients with newly diagnosed glioblastoma were enrolled on this phase II trial that investigated the addition of bevacizumab to standard radiation therapy and daily temozolomide followed by the addition of bevacizumab and irinotecan to adjuvant temozolomide. The bevacizumab was given at 10 mg/kg every 14 days beginning a minimum of 4 weeks post-craniotomy. Two weeks after radiation therapy, the patients began 6-12 cycles of 5-day temozolomide with bevacizumab and irinotecan every 14 days. The primary endpoint was the proportion of patients alive 16 months after informed consent.

Results: The therapy had moderate toxicity. Three patients came off study during radiation therapy, one of whom had a grade 2 CNS hemorrhage. Seventy patients started the post-radiation therapy, and 16 (23%) terminated this adjuvant therapy early due to toxicity. The median overall survival was 21.2 months (95% CI 17.2-25.4), and 65% of the patients were alive at 16 months (95% CI: 53.4%, 74.9%). The median progression-free survival was 14.2 months (95% CI 12-16).

Conclusions: The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, irinotecan and temozolomide for the treatment of newly diagnosed glioblastoma has moderate toxicity and may improve efficacy compared with historical controls. The results from phase III trials are required before the role of bevacizumab for newly diagnosed glioblastoma is established.